ImuVeo’s Post

Katana Labs as the #AI startup from #Saxony, which fights #cancer with the help of AI, was interviewed by the MDR MITTELDEUTSCHER RUNDFUNK. See and hear in the interview why I consider it essential that our #startup Katana Labs continues to be a model #founder for the use of AI against the #tsunami of cancer. https://lnkd.in/dreFNjzD full article: https://lnkd.in/d6QjsQKN

#9 impact investment of WIT Angels Club: Synaptiq.io is a Romanian MedTech startup revolutionising cancer prevention and treatment! 🎉🚀 🌟 Synaptiq.io offers a cutting-edge, high-accuracy image processing SaaS for contouring tumors and organs at risk with B2B solution targets radiotherapy clinics, contributing to fully-automated radiotherapy treatment planning 🎯 We are thrilled to invest in this innovative startup alongside experienced investors. 👉 11 women angel investors decided to finance this technology. If you're curious about investing in innovation, drop us a line! #womeninvestors #innovation #europe

During a time when female-led founders are seeing less in capital contributions, an Indianapolis-based angel investment group is backing a pair of women-led #startups, one of which is based in the Purdue Research Park. Of the $338,000 in checks written by 45 VisionTech Partners | VisionTech Angels investors, Amplified Sciences, Inc., led by CEO Diana Caldwell, was awarded $165,000. The life sciences diagnostic company focuses on early detection of pancreatic cancer. VisionTech Angels have invested in four startups this year, three of which are led by women. This also includes #Purdue-related startup Adipo Therapeutics, led by CEO Karen Wurster. Read more: https://ow.ly/kvMt50PuOU5 Last month, Amplified Sciences was awarded a $400,000 grant from the National Cancer Institute (NCI) to develop a test to determine if pancreatic cysts are benign or potentially malignant. Read more: https://ow.ly/z0P850PuOU4

Groupon Co-founder's healthtech startup Tempus raises $200mn Groupon Co-founder Eric Lefkofsky's biotechnology startup Tempus has raised $200 million at a valuation of $3.1 billion. Founded in September 2015, the Chicago-based startup enables physicians to deliver personalised cancer care for patients through its interactive analytical and machine learning platform. As per Forbes, Lefkofsky founded Tempus after his wife was diagnosed with breast cancer. Follow for More such Interesting Insights Ayan Nadeem #healthtech #healthcare #ai #business #startup

Embark on the narrative of Captec Medical Ltd, a startup founded by the trio of Paul Stolk, Johan De Jonghe, and Andras Guttman, offering a tangible solution in the relentless battle against cancer. 💌😷 But how, you might wonder? The weapon is Captec Medical Ltd's groundbreaking device that purifies the blood of cancer patients, removing harmful cancer cells and offering them a renewed lease on life. 🩸💉 Impressive, isn't it? Discover more about their journey, including details on: 🐾 How they conducted large-animal biosafety pilot tests? 😥 The challenges they faced while tackling the formidable adversary that cancer is? and 💪 The insights gained through our Labena Ventures accelerator programme this year? And much more on our latest blog post here 👉 - https://lnkd.in/dVW4r3wn . #startups #labenaventures #labena #accelerator #acceleratorprogramme #akcelerator #biotech #pharma #healthtech #food #founders #environment #bootcamp #investing #entrepreneurship #preseed #incubator #businessmentorship #cee #centralandeasterneurope #partner #mentor

#fundingalert 💼Company: Matter Bio 💰Funding: $7Million ⚡Round: Seed 👥Investors: quadraScope Ventures and other investors, Lifespan Vision Ventures led the round. NIH, NCI, and NIEHS provided grants for the project. Maintaining genetic integrity is the primary goal of Matter Bio, a lifespan holding business. Both endogenous and external factors continuously harm their genome as they become older. The company plans to file an IND, begin a Phase 1/2a clinical trial in solid cancer, and carry out additional research into the information theory of ageing at a genetic level with the money. George Church, Sam Sharifi, PhD, Harry Robb, Christopher Bradley Read more - https://lnkd.in/gjzaaVdE To share your startup story write us on - [email protected] #MatterBio #endogenous #geneticlevel #funding #fundingnews #news #startup #startupnews #startuprise

Granza Bio (YC W24) secures $7M seed funding from Felicis and YC to advance cancer #treatment delivery. Founders Ashwin Menon Nandakumar and Ashwin Jainarayanan met at Oxford while #working on their doctorates and bonded over a shared #interest in oncology. Inspired by groundbreaking research from Professor Michael Dustin, they decided to turn this discovery into a #startup. Initially planning to raise $2.5M, they quickly exceeded their #goal due to high #investor interest, ultimately securing $7.14M. Granza Bio’s innovative "attack particles" harness the body's immune system to target cancer and autoimmune diseases, promising safer and more effective therapies. Felicis, known for its early bets on tech giants, sees immense potential in Granza's novel therapeutic delivery mechanism. #Startups #Entrepreneurship #Innovation #DigitalMarketing #TechTrends  #AI #VentureCapital #Ecommerce #Leadership #BusinessGrowth If you spot any inaccuracies, please let us know so we can correct them. Your feedback helps us improve. Thanks! 

PitchBook's Q3 2023 Medtech Report is now live! Takeaways: - Medtech VC funding continued its upward momentum with a second straight quarter of rising investment. Top medtech deals in the quarter included Neuralink’s $280 million Series D, CMR Surgical’s $165 million late-stage round, and Harbinger Health’s $140 million Series B. - After a slow start in 2023, medtech M&A has shown signs of life, led by Advent International’s buyout of Baxter International’s biopharma solutions unit for $4.3 billion. Though we expect historically low M&A activity to continue into 2024, newly independent companies could begin to make moves as they look to consolidate market leadership.  - On the category level, cardiovascular surgical devices led the way with $487.7 million of VC investment in the quarter, followed by cancer diagnostics ($337.1 million) and surgical robotics ($334.0 million).  - Exit opportunities have been limited for medtech startups, and Q3 was no exception with no meaningful venture-backed exit occurring. Weight-loss balloon maker Allurion went public via a SPAC merger on August 2 - the firm trades at a valuation of just under $200 million—this listing would have been unlikely to garner significant interest in the 2021 IPO heyday. Please reach out to me to learn more about the data behind the report. https://lnkd.in/epr35aMp

Today, we’re announcing a new strategic investment round of $12 million, increasing our total amount raised so far to over $42 million. This latest round was led by new brain disorder fund, Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures and TruVenturo GmbH. Additionally, Jordi Parramon, PhD, CEO, General Partner and Co-Founder of Nexus NeuroTech Ventures will join the board of directors. Rune Labs CEO Brian Pepin said: “Since launching in 2021, Rune Labs’ StrivePD software has become the most widely used software by Parkinson’s patients and clinicians, and we have built complementary business lines that leverage our network and data to support both clinical development and comprehensive care management. With over 25 years of experience, Jordi brings deep knowledge in building businesses and products and the intersection of data and healthcare. This strategic partnership with Nexus NeuroTech Ventures is in line with our use of modern AI tools to support patients, clinicians, and our pharma partners, and speaks to our ambition to have a deep impact in the way Parkinson’s is understood and treated.” This funding will help propel Rune Labs with our breakthrough technologies that are changing the way people with Parkinson’s monitor their symptoms and live their lives. In 2022, our StrivePD software ecosystem for Parkinson’s disease was granted 510(k) clearance by the FDA to collect patient symptom data, including #tremor and #dyskinesia, via Apple Watch. Since then, we’ve continued to grow and establish partnerships on our path to revolutionizing precision neurology technology. https://lnkd.in/dvn_Hzq9 #Parkinsons #braindata #digitalhealth #healthtechnology #parkinsonsdisease #funding #fundraising #NexusNeuroTech #investment #businessgrowth